Navigation Links
Pradaxa Lawsuits Mount, as Claims in Federal Multidistrict Litigation Exceed 2,000, Bernstein Liebhard LLP Reports
Date:12/27/2013

fe Medicine Practices (ISMP) reported that Pradaxa had been named in more than 3,200 adverse event reports made to the U.S. Food & Drug Administration (FDA) in 2012, including 582 fatalities. According to the ISMP analysis, Pradaxa led all other drugs in FDA adverse event reports that year. By contrast, warfarin was the subject of just 861 reports, including 56 deaths. *

The federal multidistrict litigation for Pradaxa lawsuits was established in August 2012. According to court documents, only 21 claims were transferred to the proceeding at that time. The litigation’s first bellwether trial is scheduled to begin in August 2014.

Alleged victims of Pradaxa bleeding may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury-related damages. To learn more about filing a Pradaxa lawsuit, please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome wit
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Upcoming Status Conference in Federal Pradaxa Litigation
2. Federal Judge Fines Boehringer Ingelheim More Than $931K Due To Missing Evidence in Pradaxa Lawsuits Disturbs Wright & Schulte LLC
3. Pradaxa Lawsuit News: Bernstein Liebhard LLP Notes Judge’s Decision to Fine Boehringer Ingelheim for Failing to Preserve Documents Relevant to Pradaxa Bleeding Claims
4. As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
5. Pradaxa Lawsuit News: Wright & Schulte LLC Reports on Growing Pradaxa Bleeding Litigation, As Number of Filings Exceed 1,800
6. Pradaxa Lawsuit News: Bernstein Liebhard LLP Reports on November Status Conference in Federal Pradaxa Bleeding Litigation
7. Pradaxa Bleeding Allegations Lawyer: Resource4thePeople Reports New Study May Produce Treatment to Reverse Anti-Clotting Medication Effects
8. Pradaxa Lawsuits Continue to Mount, With Filing of New Pradaxa Wrongful Death Claim in Pennsylvania by Wright & Schulte LLC
9. Pradaxa Lawsuits Progress, as Bernstein Liebhard LLP Notes Establishment of Bellwether Case Selection Protocol in Federal Pradaxa Bleeding Litigation
10. Pradaxa Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Issuance of New Order in Federal Pradaxa Bleeding Litigation
11. New Data on Pradaxa Bleeding Side Effects Draws Comment from Pradaxa Lawsuit Lawyers at Wright & Schulte LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... April 22, 2014: The Association for Molecular Pathology ... Journal of Molecular Diagnostics on recommendations for ... and master,s levels of education. The report was ... Task Force of the AMP Training and Education ... need of educating future medical laboratory scientists appropriately ...
(Date:4/22/2014)... rabbits, Johns Hopkins scientists have found a way to ... the development of atherosclerosis, the main cause of heart ... among humans. The condition develops when fat builds inside ... and hardened, greatly reducing their ability to feed oxygen-rich ... In a series of experiments, described April 7 in ...
(Date:4/22/2014)... news release is available in German . ... are important intracellular signaling molecules, but their mode of ... aspects of cellular function and behavior, while at high ... membranes and DNA. To analyze how redox signaling unfolds ... optical microscopy technique has been developed jointly by the ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... all seem to know who we say is neurotic and ... unable to act but simply doesn,t want to., ... of nearly 4,000 college students in 19 countries has uncovered ... and moving forward with life. Turns out that when they ... don,t like it as much as non-neurotics. Therefore persuasive communications ...
Breaking Medicine News(10 mins):Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:Neuroimaging: Live from inside the cell 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:Neurotics don't just avoid action: They dislike it 2
... novel pancreatic cancer vaccine shows promise in improving survival when ... University Hospitals Case Medical Center,s Seidman Cancer Center and Case ... was presented today (embargoed 11:00 am ET) at the Annual ... part of Digestive Disease Week in San Diego. ...
... thousands of psychiatrists attend their field,s largest annual meeting ... drug treatments report overwhelmingly on positive results. ... the Journal of Clinical Psychopharmacology by two ... University, who analyzed the presentations given at two recent ...
... The national gastroenterology societies have issued a new document ... Sedation Curriculum for Gastrointestinal Endoscopy (MSCGE) grew out ... to the training of procedure sedation. The document is ... of Gastroenterology , GIE:Gastrointestinal Endoscopy , Hepatology ...
... The Food and Drug Administration has approved a new ... disorders. The test, or assay, was developed by an expert ... Lawrence Schwartz, M.D., Ph.D., chair of the Division of ... Professor of Medicine at VCU, has spent more than 30 ...
... Lies Van Nieuwenhove, researcher at the Antwerp Institute of ... the sleeping sickness parasite. They can be used in ... dangerous parasites. Each year many thousands of ... parasite, a trypanosome, which is transmitted by the bite ...
... TUESDAY, May 22 (HealthDay News) -- Fear of spiders, a ... therapy session, according to a small new study. People ... hold a tarantula after a two- or three-hour therapy session, ... six months, the Northwestern University researchers reported. The lasting ...
Cached Medicine News:Health News:Researchers present new findings for novel pancreatic cancer vaccine 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 2Health News:Bias found in mental health drug research presented at major psychiatric meeting 3Health News:Gastroenterology Societies issue sedation curriculum for gastrointestinal endoscopy 2Health News:FDA clears test developed in partnership with VCU researcher 2Health News:Better tests for sleeping sickness 2Health News:Spider-Phobes May Get Quick Relief 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014 HeartWare ... leading innovator of less invasive, miniaturized circulatory support technologies ... today announced that it expects revenues for the fourth ... expected full-year 2013 revenues to approximately $208 million. ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
Radiopaque markers indicate the proximal and distal ends of the balloon. Supplied sterile in peel-open packages. Intended for one-time use....
... Ureteral Access Sheath, you can have all ... - plus an entirely new level of ... designed with a proprietary dual lumen design, ... channel for a variety of procedural steps ...
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Fr Straight Channel; 33 or 42 cm ... Operating Ureteroscopes offer a small distal diameter ... to the ureter for diagnosis and treatment. ... ideal for large operating instruments, mechanical (Lithoclast) ...
Medicine Products: